UPDATE: Lowe's (LOW) PT Raised to $300 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Lowe's (LOW) PT Raised to $300 at Jefferies
December 16, 2021 7:51 AM ESTJefferies analyst Jonathan Matuszewski raised the price target on Lowe's (NYSE: LOW) to $300.00 (from $290.00) while maintaining a Buy rating.
The analyst commented, "We're not surprised management expects home improvement industry spend to fall in '22 after record-setting growth in '20 & '21. While... More
Lowe's (LOW) Stock Opens Lower as FY22 Guidance Misses EPS and Revenue Consensus Estimates
December 15, 2021 9:43 AM ESTShares of Lowes (NYSE: LOW) opened about 1% lower today after the company presented its 2022 outlook today at its 2022 Financial Outlook webcast event.
Lowes is calling for sales between $94 billion to $97 billion for the full year 2022, which includes an extra week compared to 2021 that... More
Pre-Open Stock Movers 12/15: (QNRX) (GMTX) (GRTX) Higher; (RBLX) (LESL) (MGNI) Lower (more...)
December 15, 2021 9:24 AM ESTPre-Open Stock Movers:
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) 61% HIGHER; announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with Orpharm LLC (Orpharm) for QRX003, the Company's investigational treatment for Netherton Syndrome, a rare and devastating genetic disease, for which there is currently no available treatment or cure.
Lowe's expects 2022 sales to miss estimates as home improvement demand cools
December 15, 2021 8:15 AM EST(Reuters) -Lowe's Cos Inc on Wednesday forecast full-year 2022 revenue and profit below analysts' estimates, signaling that a pandemic-driven surge in demand for home improvement products would wane.
Lowe's said it expects same-store sales to fall as much as 3% next year, as the easing of coronavirus restrictions encourages Americans to leave behind some pandemic shopping... More
Home Depot (HD) Trades Lower in Sympathy Following Guidance from Lowe's (LOW)
December 15, 2021 7:54 AM ESTHome Depot (NYSE: HD) Trades Lower in Sympathy Following Guidance from Lowe's (NYSE: LOW)
Lowe's -4%Home Depot -2%... MoreLowe's Cos. (LOW) Issues 2022 Financial Guidance
December 15, 2021 7:46 AM ESTLowe's Companies, Inc. (NYSE: LOW) is hosting its 2022 Financial Outlook webcast today.
Today's presentations include the company's priorities for 2022 with a focus on its Total Home Strategy aimed at taking market share, driving productivity, and providing an integrated omni-channel shopping experience. Additionally, the company plans to review its 2022 financial outlook and capital allocation commitments.
"I am pleased to share our plans for 2022, including how we will drive further market share gains across DIY and Pro through our Total Home Strategy," commented Marvin R. Ellison, Lowe's chairman, president, and CEO.
"We... More

